Rafarma Pharmaceuticals strengthens its position in Central Asia
Rafarma Pharmaceuticals strengthens its position in Central Asia
Nicosia, Cyprus, April 29, 2022 (GLOBE NEWSWIRE) -- Representatives of Rafarma Pharmaceuticals, Inc. (OTC: RAFA) visited Uzbekistan and discussed the prospects for the company's development in the territory of the innovative research and production pharmaceutical cluster "Tashkent Pharma Park". Rafarma Pharmaceuticals is not new to the Central Asian market, the company has been operating there for a long time and plans to increase its presence by creating local production.
塞浦路斯尼科西亚,2022年4月29日(环球通讯社)--拉法玛制药公司(场外交易代码:RAFA)的代表访问了乌兹别克斯坦,并讨论了该公司在创新研究和生产制药集群“塔什干制药园”领土上的发展前景。Rafarma PharmPharmticals对中亚市场来说并不新鲜,该公司在那里已经运营了很长时间,并计划通过在当地建立生产来扩大自己的存在。
Over the next three years, the company plans to build a plant there designed according to all Industry 4.0 standards: a flexible industrial base that can easily, quickly and cost-effectively undergo significant modernization and modification depending on production tasks, drugs and required technologies.
在接下来的三年里,该公司计划在那里建造一座按照所有Industry 4.0标准设计的工厂:一个灵活的工业基础,可以根据生产任务、药物和所需技术轻松、快速、经济高效地进行重大现代化和改造。
The plant will include two production units:
该工厂将包括两个生产单元:
- production of sterile preparations for the market of Uzbekistan and the countries of Central Asia
- production of fractionated blood plasma elements and other products in the form of frozen plasma and blood factors, as well as the development of a network of laboratories for plasma procurement
- 面向乌兹别克斯坦和中亚国家市场的无菌制剂生产
- 以冷冻血浆和血液因子的形式生产分级血浆元素和其他产品,以及发展血浆采购实验室网络
Rafarma Pharmaceuticals is the initiator of the development of new approaches to the drugs from blood plasma creation in Uzbekistan. The company's project, which became a part of a list of measures to accelerate the development of the pharmaceutical industry in Uzbekistan in 2022-2026, will consist of two stages: the creation of a modern certified laboratories network for plasma collection and then the creation of a plant for its fractionation. In 4-5 years, the business's expected revenue will be tens of millions of dollars.
Rafarma制药公司是乌兹别克斯坦开发血浆药物新方法的发起人。该公司的项目成为2022-2026年加快乌兹别克斯坦制药业发展的措施清单的一部分,将包括两个阶段:创建一个用于血浆采集的现代认证实验室网络,然后创建一个用于血浆分离的工厂。在4-5年内,该业务的预期收入将达到数千万美元。
To date, the country's government is working on legislative changes in the principles of working with blood plasma in the medical sector and is also preparing documents to allow the based on it medicine export. The implementation of the Rafarma Pharmaceuticals project will begin as soon as the necessary regulatory framework creates in the government, which is expected to happen soon.
到目前为止,该国政府正在努力对医疗部门使用血浆的原则进行立法改革,并正在准备文件,允许以此为基础的药品出口。一旦政府建立了必要的监管框架,Rafarma制药项目的实施将立即开始,预计很快就会开始。
Uzbekistan ranks first among the Eastern Europe countries in terms of economic growth, and the expected changes will only strengthen the country's influence in the pharmaceutical market.
乌兹别克斯坦的经济增长在东欧国家中排名第一,预期中的变化只会加强该国在药品市场的影响力。
ABOUT RAFARMA PHARMACEUTICALS:
关于RAFARMA制药公司:
Rafarma Pharmaceuticals is a diversified pharmaceutical company dedicated to the new treatments and solutions development for patients in various fields. Regularly cooperating with leading research institutes and pharmaceutical companies around the world, the business has earned a reputation as a reliable manufacturer and distributor. Rafarma Pharmaceuticals has more than 25 programs in molecular biology, nuclear medicine, immunology, sustainable packaging and many other fields at the moment.
拉法玛制药是一家多元化的制药公司,致力于为各个领域的患者开发新的治疗方法和解决方案。该公司经常与世界各地的领先研究机构和制药公司合作,赢得了可靠制造商和分销商的声誉。拉法玛制药目前在分子生物学、核医学、免疫学、可持续包装等许多领域拥有25个以上的项目。
For more information, please visit
欲了解更多信息,请访问
FORWARD-LOOKING STATEMENT:
前瞻性陈述:
Forward-Looking Statements: This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate," or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
前瞻性陈述:本新闻稿包含1934年证券交易法第21E节所指的“前瞻性陈述”。除文中包含的历史性陈述外,本新闻稿中的陈述均为前瞻性陈述。在不限制上述一般性的情况下,诸如“可能”、“将”、“到”、“计划”、“预期”、“相信”、“预期”、“打算”、“可能”、“将”、“估计”或“继续”等词语或其负面的其他变体或类似术语旨在识别前瞻性表述。前瞻性表述涉及已知和未知的风险、不确定性和其他因素,可能导致我们的实际结果、业绩或成就与前瞻性表述明示或暗示的任何未来结果、业绩或成就大不相同。此外,前瞻性陈述仅代表我们管理层截至本文发布之日的信念和假设。有关可能导致实际结果与这些前瞻性陈述大不相同的因素的更多信息可在该公司向场外交易市场提交的文件中获得。除非法律要求,否则我们没有义务公开更新这些前瞻性陈述,或更新实际结果可能与这些前瞻性陈述中预期的结果大不相同的原因,即使未来有新的信息。
CONTACTS:
RAFARMA PHARMACEUTICALS
Info@rafapharm.com
(307) 429-2029
联系人:
RAFARMA制药公司
邮箱:Info@rafapharm.com
(307) 429-2029
Source: Rafarma Pharmaceuticals, Inc.
消息来源:Rafarma制药公司